Login to Your Account



Menlo itching to solve pruritus with $50M round for serlopitant

By Marie Powers
News Editor

Tuesday, July 18, 2017

Menlo Therapeutics Inc. added new faces to its stable of investors in a $50 million series C designed to move serlopitant, the company's NK-1 receptor antagonist, into a pivotal program as a once-daily oral treatment for the lead indication of chronic pruritus.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription